StockNews.com began coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Free Report) in a research report sent to investors on Friday. The firm issued a hold rating on the medical research company’s stock.
Accelerate Diagnostics Stock Performance
Shares of AXDX stock opened at $1.28 on Friday. Accelerate Diagnostics has a 1 year low of $0.73 and a 1 year high of $7.58. The business’s fifty day moving average is $1.23 and its 200-day moving average is $1.10. The stock has a market cap of $28.22 million, a PE ratio of -0.31 and a beta of 0.57.
Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The medical research company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.16). The firm had revenue of $2.92 million for the quarter, compared to the consensus estimate of $3.00 million. Equities research analysts predict that Accelerate Diagnostics will post -2.37 earnings per share for the current year.
Hedge Funds Weigh In On Accelerate Diagnostics
About Accelerate Diagnostics
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
Read More
- Five stocks we like better than Accelerate Diagnostics
- 3 Stocks to Consider Buying in October
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- The 3 Best Blue-Chip Stocks to Buy Now
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.